| Filed On | Filing |
|---|---|
| 17 Sep 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
(a) Purpose. The TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan (the “Plan”) is intended to provide equity-based and cash incentive awards that qualify as employment inducement awards under the Nasdaq Rule. The Plan is in... |
| 30 Apr 2026 |
8-K/A: Other Events
Unless the context indicates otherwise in this Unaudited Pro Forma Condensed Combined Financial Information, references to “TuHURA,” “TuHURA Biosciences, Inc.” the “Company,” “we,” “us,” “our” and similar terms refer to TuHURA Bioscience... |
| 12 Aug 2025 |
8-K/A: Financial Statements and Exhibits
Unless the context indicates otherwise in this Unaudited Pro Forma Consent Combined Financial Information, references to “TuHURA,” “TuHURA Biosciences, Inc.” the “Company,” “we,” “us,” “our” and similar terms refer to TuHURA Biosciences,... |
| 07 May 2025 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 14 Nov 2024 |
8-K/A: Completion of Acquisition or Disposition of Assets
As of September 30, 2024 and December 31, 2023 and for the three and nine months ended September 30 2024 and 2023. |
| 24 Aug 2020 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined financial statements were prepared in accordance with the regulations of the SEC and give effect to (i) the acquisition of Adgero Biopharmaceuticals Holdings, Inc. (“Adgero”) by Kintar... |
| 15 Aug 2019 |
8-K/A: Other Events
The undersigned, DelMar Pharmaceuticals, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Sta... |
| 03 Jun 2019 |
8-K/A: Financial Statements and Exhibits
This Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2019, between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including i... |
| 17 May 2018 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported in the Original Form 8-K, in a non-binding, advisory vote on the frequency of future Say on Pay votes held at the 2018 Annual Meeting, 1,456,454 shares voted for one year, 306,927 shares voted for two years, 7,992,... |
| 28 Mar 2013 |
8-K/A: Completion of Acquisition or Disposition of Assets
This Management Discussion and Analysis (“MD&A”) contains “forward-looking statements”, which represent our projections, estimates, expectations or beliefs concerning among other things, financial items that relate to management’s future... |
| 14 Mar 2013 |
8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +6 more
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS AGREEMENT. THE COPY FILED HEREWITH OMITS THE INFORMATION SUBJECT TO THE CONFIDENTIALITY REQUEST. A COMPLETE VERSION OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE SECUR... |
Loading...